Document is current
Any future updates will be listed below
-
Authors
Thompson, Craig P. https://orcid.org/0000-0001-9248-9365
Lourenço, José https://orcid.org/0000-0002-9318-2581
Walters, Adam A.
Obolski, Uri
Edmans, Matthew
Palmer, Duncan S. https://orcid.org/0000-0002-0824-0047
Kooblall, Kreepa
Carnell, George W.
O’Connor, Daniel https://orcid.org/0000-0002-6902-9886
Bowden, Thomas A.
Pybus, Oliver G.
Pollard, Andrew J.
Temperton, Nigel J. https://orcid.org/0000-0002-7978-3815
Lambe, Teresa
Gilbert, Sarah C. https://orcid.org/0000-0002-6823-9750
Gupta, Sunetra
-
Funding
Funding for this research was provided by:
EC | European Research Council (614725, 268904)
- License Information
-
More Information
Article History
Received: 5 April 2018
Accepted: 6 August 2018
First Online: 21 September 2018
Competing interests
: C.P.T and S.G are named as inventors on a patent application for an influenza vaccine targeting the epitope conformations outlined in this paper (PCT/GB2017/052510). It should be noted in the interests of full disclosure that S.C.G is a co-founder of Vaccitech, a spin-out company from the University of Oxford, which is developing an MVA-NP + M1 influenza vaccine. However, the MVA-NP + M1 vaccine as well as Vaccitech are entirely separate from and in no way are connected to the work undertaken in this paper as well as the vaccine proposed in the paper. All other authors report no potential conflicts.
